Even Brief E-Cigarette Use Can Cause Lasting Lung Damage and Weaken Defenses Against Respiratory Viruses, Study Finds


DENVER - Just days of e-cigarette vapor exposure can injure the lungs' most delicate tissue and leave it more vulnerable to viral infection, according to a study led by National Jewish Health researchers and published in JCI Insight.

The research team studied human lung epithelial and endothelial cells, along with precision-cut human lung tissue, all taken from the distal lung — the deep, delicate region where oxygen passes into the bloodstream. They exposed these tissues to e-cigarette vapor alone, and separately tested vapor exposure followed by infection with a respiratory virus, in preclinical models. Within 24 hours, e-cigarette vapor damaged the protective barrier of the distal lung, triggered cellular stress, impaired cells’ internal process for clearing damaged components, slowed cell growth and repair, and increased cell death.

Strikingly, signs of lung stress persisted 10 days after just a five-day exposure period ended. The team observed lasting changes in barrier function, tissue remodeling, and Th1 immunity — a branch of the immune system critical to fighting viral infections.

Prior vaping exposure also increased SARS-CoV-2 viral burden and suppressed several antiviral genes following infection.

“Our findings suggest that even short-term vaping exposure can initiate injury in the deepest and most delicate regions of the lung,” said senior author Irina Petrache, MD, pulmonologist and chief of the Division of Pulmonary, Critical Care and Sleep Medicine at National Jewish Health. “Importantly, some effects persisted after exposure ended and altered the immune response to a subsequent viral infection.”

The findings, which will need to be confirmed in future studies in people, point to biological mechanisms that may help explain why vaping has been linked to lung injury and greater susceptibility to respiratory infections. The researchers noted that repeated exposure could potentially contribute to chronic lung disease by sustaining cellular injury and disrupting normal repair.
 

National Jewish Health is the leading respiratory hospital in the nation delivering excellence in multispecialty care and world class research. Founded in 1899 as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of children and adults with respiratory, cardiac, immune and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit njhealth.org or the media resources page.


We have many faculty members, from bench scientists to clinicians, who can speak on almost any aspect of respiratory, immune, cardiac and gastrointestinal disease as well as lung cancer and basic immunology.

Our team is available to arrange interviews, discuss events and story ideas.

Make an Appointment